Anti-Mouse CLEC9A/CD370 Antibody (7H11) 

Anti-Mouse CLEC9A/CD370 Antibody (7H11) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse CLEC9A/CD370. Anti-Mouse CLEC9A/CD370 Antibody (7H11) reacts with mouse CLEC9A (C-type lectin domain family member 9A) and blocks CLEC9A. Anti-Mouse CLEC9A/CD370 Antibody (7H11) can be used for the researches of cancer and immunology, such as B16.F10-OVA tumor^[1][2].

Rat IgG1 kappa

Rat IgG1 kappa, Isotype Control

Mouse

CLEC9A/CD370

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse CLEC9A/CD370 Antibody (7H11) (400 μg, i.p., at days 5, 7, 9, and 11) blocks necrotic cell sensor CLEC9A and does not affect tumor restriction or animal survival extension by necroptotic fibroblasts in B16.F10-OVA tumor mice^[1].
Anti-Mouse CLEC9A/CD370 Antibody (7H11) (200 μg, s.c., a single dose) requires adjuvant (polyICLC) to induce humoral responses in C57/BL6 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

232414  [NCBI]

Q8BRU4-4

ELISA, FACS, Functional assay, Research in vivo

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

colorless

[Anti-Mouse CLEC9A/CD370 Antibody (7H11)]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Snyder AG, et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol. 2019 Jun 21;4(36):eaaw2004.  [Content Brief]

  [2]. Li J, et al. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol. 2015 Mar;45(3):854-64.  [Content Brief]